Quarterly report pursuant to Section 13 or 15(d)

Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail)

v3.24.3
Share-Based Compensation - Summary of Activity Under Share-Based Compensation Plans (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Outstanding and nonvested, Beginning Balance, Number of Shares [1]     6,118    
Granted, Number of Shares     5,416    
Vested, Number of Shares     (1,913)    
Forfeited, Number of Shares [2]     (2,328)    
Outstanding and nonvested, Ending Balance, Number of Shares 7,293   7,293   6,118 [1]
Number of Shares, Expected to vest 6,914   6,914    
Outstanding and nonvested, Beginning Balance, Weighted Average Grant Date Fair Value Per Share [1]     $ 20.76    
Granted, Weighted Average Grant Date Fair Value Per Share     9.42    
Vested, Weighted Average Grant Date Fair Value Per Share     24.25    
Forfeited, Weighted Average Grant Date Fair Value Per Share [2]     14.83    
Outstanding and nonvested, Ending Balance, Weighted Average Grant Date Fair Value Per Share $ 13.32   13.32   $ 20.76 [1]
Expected to vest, Ending Balance, Weighted Average Grant Date Fair Value Per Share $ 12.71   $ 12.71    
SARs [Member]          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of Awards Outstanding, Beginning Balance [3]     4,340    
Granted, Number of Awards [4]     7,364    
Exercised, Number of Awards     0    
Forfeited, Number of Awards [5]     (606)    
Number of Awards Outstanding, Ending Balance [3] 11,098   11,098   4,340
Number of Awards Exercisable, Ending Balance [6] 1,937   1,937    
Number of Awards Vested and expected to vest, Ending Balance [7] 7,532   7,532    
Weighted Average Exercise Price Per Award Outstanding, Beginning Balance [3]     $ 19.85    
Granted, Weighted Average Exercise Price Per Award [4]     8.6    
Exercised, Weighted Average Exercise Price Per Award     0    
Forfeited, Weighted Average Exercise Price Per Award [5]     22.59    
Weighted Average Exercise Price Per Award Outstanding, Ending Balance [3] $ 12.24   12.24   $ 19.85
Exercisable, Weighted Average Exercise Price Per Award, Ending Balance [6] 23.22   23.22    
Weighted Average Exercise Price Per Award, Vested and expected to vest, Ending Balance [7] $ 14.15   $ 14.15    
Weighted Average Remaining Contractual Term Outstanding [3]     7 years 3 months 18 days   6 years 4 months 24 days
Exercisable Weighted Average Remaining Contractual Term [6]     3 years 6 months    
Weighted Average Remaining Contractual Term, Vested and expected to vest [7]     7 years 3 months 18 days    
Aggregate Intrinsic Value Outstanding [3],[8] $ 0.0   $ 0.0   $ 2.4
Exercisable, Aggregate Intrinsic Value [6],[8] 0.0   0.0    
Aggregate Intrinsic Value, Vested and expected to vest [7],[8] $ 0.0   $ 0.0    
Granted, Weighted Average Grant Date Fair Value Per Share $ 5.36 $ 10.3 $ 4.52 $ 7.93  
[1] Includes 190,412 and 307,116 performance-based restricted stock units as of September 30, 2024 and December 31, 2023, respectively, which represents the maximum amount that can vest.
[2] Includes 116,704 performance-based restricted stock units.
[3] Includes 4.0 million and 0.6 million performance condition SARs as of September 30, 2024 and December 31, 2023, respectively.
[4] Includes 3.4 million performance condition SARs granted to a consultant.
[5] Includes less than 0.1 million performance condition SARs.
[6] Includes 0.6 million performance condition SARs.
[7] Includes 0.6 million performance condition SARs.
[8] The intrinsic value is the amount by which the current market value of the underlying stock exceeds the exercise price of the stock awards.